{
    "organizations": [],
    "uuid": "0c966b67d52549a3bd5cffecb5ccbf36eaf3acb6",
    "author": "",
    "url": "https://www.reuters.com/article/brief-advantagene-announces-clinical-tri/brief-advantagene-announces-clinical-trial-collaboration-idUSASC09Y18",
    "ord_in_thread": 0,
    "title": "BRIEF-Advantagene Announces Clinical Trial Collaboration",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 22 AM / Updated 8 minutes ago BRIEF-Advantagene Announces Clinical Trial Collaboration Reuters Staff\nApril 27 (Reuters) - Bristol-Myers Squibb Co: * ADVANTAGENE ANNOUNCES CLINICAL TRIAL COLLABORATION\n* ADVANTAGENE INC SAYS COMPANY ENTERED INTO A CLINICAL TRIAL COLLABORATION WITH BRISTOL-MYERS SQUIBB\n* ADVANTAGENE - COLLABORATION TO EVALUATE SAFETY, EFFICACY OF CO’S INVESTIGATIONAL GENE MEDIATED CYTOTOXIC IMMUNOTHERAPY COMBINED WITH BRISTOL’S OPDIVO\n* ADVANTAGENE - ITS INVESTIGATIONAL GMCI COMBINED WITH OPDIVO IS TO TREAT NEWLY DIAGNOSED MALIGNANT GLIOMA PATIENTS GETTING SURGERY WITH/WITHOUT TEMOZOLOMIDE Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)",
    "published": "2018-04-27T14:20:00.000+03:00",
    "crawled": "2018-04-27T15:01:23.003+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "updated",
        "minute",
        "ago",
        "announces",
        "clinical",
        "trial",
        "collaboration",
        "reuters",
        "staff",
        "april",
        "reuters",
        "squibb",
        "co",
        "advantagene",
        "announces",
        "clinical",
        "trial",
        "collaboration",
        "advantagene",
        "inc",
        "say",
        "company",
        "entered",
        "clinical",
        "trial",
        "collaboration",
        "squibb",
        "advantagene",
        "collaboration",
        "evaluate",
        "safety",
        "efficacy",
        "co",
        "investigational",
        "gene",
        "mediated",
        "cytotoxic",
        "immunotherapy",
        "combined",
        "bristol",
        "opdivo",
        "advantagene",
        "investigational",
        "gmci",
        "combined",
        "opdivo",
        "treat",
        "newly",
        "diagnosed",
        "malignant",
        "glioma",
        "patient",
        "getting",
        "surgery",
        "temozolomide",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}